A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement.
Elena FountzilasElangovan KrishnanFilip JankuSiqing FuDaniel D KarpAung NaingVivek SubbiahDavid S HongSarina A Piha-PaulDavid J ViningApostolia-Maria TsimberidouPublished in: Cancer chemotherapy and pharmacology (2018)
HAI oxaliplatin combined with capecitabine +/- bevacizumab was well-tolerated and was associated with favorable outcomes in selected patients.
Keyphrases
- metastatic colorectal cancer
- advanced cancer
- clinical trial
- palliative care
- end stage renal disease
- newly diagnosed
- ejection fraction
- phase iii
- chronic kidney disease
- metastatic breast cancer
- prognostic factors
- open label
- type diabetes
- squamous cell carcinoma
- randomized controlled trial
- high dose
- phase ii
- study protocol
- insulin resistance
- adipose tissue
- weight loss